TriangleLiposome-encapsulated… (NCT03629171)
Liposome-encapsulated Daunorubicin-Cytarabine trial for Recurrent Acute Myeloid Leukemia (NCT03629171). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with relapsed or refractory acute myeloid leukemia, or untreated disease at ages eighteen to sixty-nine. Acute promyelocytic leukemia and newly diagnosed core-binding-factor leukemia are excluded.
The idea: combine CPX-351 infusions with oral venetoclax. CPX-351 packages daunorubicin and cytarabine; venetoclax blocks BCL-2, which helps cancer cells survive. Treatment allows up to two induction and four consolidation cycles. Venetoclax is taken on days two through twenty-one of each four-week cycle. Researchers assess remission and safety.
This phase 2 study plans 72 patients. Tapan Kadia leads MD Anderson's recruiting Houston site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.